Tagrisso（Osimertinib、之前又称为AZD9291、中文名：塔格瑞斯）

据印度代购了解，2015年11月13日，美国FDA批准了阿斯利康的Tagrisso（Osimertinib mesylate，又名AZD9291）上市，其用于治疗表皮生长因子受体（EGFR）T790M突变或对其它EGFR抑制剂耐药的晚期非小细胞肺癌患者。Tagrisso属于第三代口服的、不可逆的选择性EGFR突变抑制剂，可作用于激活的和抗性突变的EGFR。Tagrisso目前国内还尚未上市。

Astrazeneca's Tagrisso (Osimertinib Mesylate, also known as AZD9291) was approved by the US FDA on November 13, 2015. It is used to treat advanced non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) T790M mutations or resistance to other EGFR inhibitors. Tagrisso belongs to the third generation of oral, irreversible selective EGFR mutation inhibitors that act on both active and resistant EGFR mutations. Tagrisso is not yet available in China.

据印度代购了解，印度版塔格瑞斯官方零售价：87000卢比（约8700人民币）/盒

According to Daigou India, the official retail price of Taggaris in India: Rs 87,000 (about 8700 YUAN)/box